/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.
A new study has confirmed that the currently available COVID-19 vaccines are safe and effective in patients with cancer. The seroconversion rate among the majority of cancer patients was high, suggesting that vaccines helped them to develop SARS-CoV-2 antibodies.
Despite fears that their immune systems wouldn t respond to COVID vaccines, cancer patients are finding the vaccines DO work for them. 94% developed antibodies after vaccination in a new study.